ArticleVirologica Sinica2026
Antiviral activity of Saponin C from Liriope muscari against influenza A virus and SARS-CoV-2.
Article in Virologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Saponin C (also known as DT-13) is the dominant ingredient extracted from the tuber of Liriope muscari (Decne.) L. H. Bailey, which exhibits multiple pharmacological activities, including anti-tumor, anti-thrombotic, cardioprotective and anti-inflammatory effects. However, its antiviral potential remains unexplored. This study aimed to investigate the inhibitory activity and underlying mechanisms of Saponin C against both influenza A virus (IAV) and SARS-CoV-2. In vitro experiments demonstrated that Saponin C dose-dependently inhibited IAV replication in MDCK and A549 cells. Time-of-addition assay revealed that Saponin C targeted the post-entry stages of IAV replication by impairing viral ribonucleoprotein (vRNP) function. This was evidenced by the suppression of viral polymerase activity, reduction of viral RNA synthesis, and delayed nuclear export of vRNP. The in vivo efficacy was further validated in a lethal H1N1 mouse model, where both prophylactic and therapeutic administration of Saponin C significantly improved the survival rate of infected mice, reduced viral loads in lung tissues, and attenuated virus-induced pulmonary inflammation in a dose-dependent manner. Beyond IAV, Saponin C also effectively inhibited SARS-CoV-2 infection by blocking viral entry, specifically through interfering with the binding of viral spike protein to the human ACE2 receptor and suppressing spike-mediated membrane fusion. Collectively, these findings demonstrate that Saponin C possesses antiviral potential against IAV and SARS-CoV-2, and may thus serve as a promising therapeutic agent for the treatment of respiratory viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.